Current and historical daily PE Ratio for DMK Pharmaceuticals Corp (
FRA:CY3
) from 1990 to Jun 10 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. DMK Pharmaceuticals stock (FRA:CY3) PE ratio as of Jun 10 2024 is 0.
More Details
DMK Pharmaceuticals Corp (FRA:CY3) PE Ratio (TTM) Chart
DMK Pharmaceuticals Corp (FRA:CY3) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1207
- 1
- 2
- 3
- 4
- 5
- 6
- 14
DMK Pharmaceuticals PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-10 | At Loss | 2023-12-11 | At Loss |
2024-02-13 | At Loss | 2023-12-08 | At Loss |
2024-02-12 | At Loss | 2023-12-07 | At Loss |
2024-02-09 | At Loss | 2023-12-06 | At Loss |
2024-02-08 | At Loss | 2023-12-05 | At Loss |
2024-02-07 | At Loss | 2023-12-04 | At Loss |
2024-02-06 | At Loss | 2023-12-01 | At Loss |
2024-02-05 | At Loss | 2023-11-30 | At Loss |
2024-02-02 | At Loss | 2023-11-29 | At Loss |
2024-02-01 | At Loss | 2023-11-28 | At Loss |
2024-01-31 | At Loss | 2023-11-27 | At Loss |
2024-01-30 | At Loss | 2023-11-24 | At Loss |
2024-01-29 | At Loss | 2023-11-23 | At Loss |
2024-01-26 | At Loss | 2023-11-22 | At Loss |
2024-01-25 | At Loss | 2023-11-21 | At Loss |
2024-01-24 | At Loss | 2023-11-20 | At Loss |
2024-01-23 | At Loss | 2023-11-17 | At Loss |
2024-01-22 | At Loss | 2023-11-16 | At Loss |
2024-01-19 | At Loss | 2023-11-15 | At Loss |
2024-01-18 | At Loss | 2023-11-14 | At Loss |
2024-01-17 | At Loss | 2023-11-13 | At Loss |
2024-01-16 | At Loss | 2023-11-10 | At Loss |
2024-01-12 | At Loss | 2023-11-09 | At Loss |
2024-01-11 | At Loss | 2023-11-08 | At Loss |
2024-01-10 | At Loss | 2023-11-07 | At Loss |
2024-01-09 | At Loss | 2023-11-06 | At Loss |
2024-01-08 | At Loss | 2023-11-03 | At Loss |
2024-01-05 | At Loss | 2023-11-02 | At Loss |
2024-01-04 | At Loss | 2023-11-01 | At Loss |
2024-01-03 | At Loss | 2023-10-31 | At Loss |
2024-01-02 | At Loss | 2023-10-30 | At Loss |
2024-01-01 | At Loss | 2023-10-27 | At Loss |
2023-12-29 | At Loss | 2023-10-26 | At Loss |
2023-12-28 | At Loss | 2023-10-25 | At Loss |
2023-12-27 | At Loss | 2023-10-24 | At Loss |
2023-12-25 | At Loss | 2023-10-23 | At Loss |
2023-12-22 | At Loss | 2023-10-20 | At Loss |
2023-12-21 | At Loss | 2023-10-19 | At Loss |
2023-12-20 | At Loss | 2023-10-18 | At Loss |
2023-12-19 | At Loss | 2023-10-17 | At Loss |
2023-12-18 | At Loss | 2023-10-16 | At Loss |
2023-12-15 | At Loss | 2023-10-13 | At Loss |
2023-12-14 | At Loss | 2023-10-12 | At Loss |
2023-12-13 | At Loss | 2023-10-11 | At Loss |
2023-12-12 | At Loss | 2023-10-10 | At Loss |
DMK Pharmaceuticals Corp (FRA:CY3) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![DMK Pharmaceuticals Corp DMK Pharmaceuticals Corp logo](https://static.gurufocus.com/logos/0C0000078G.png?14)
DMK Pharmaceuticals Corp
NAICS : 325412
SIC : 2834
ISIN : US00547W2089
Description
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.